ATE447610T1 - Kristalliner vap-1 und verwendung - Google Patents

Kristalliner vap-1 und verwendung

Info

Publication number
ATE447610T1
ATE447610T1 AT04734701T AT04734701T ATE447610T1 AT E447610 T1 ATE447610 T1 AT E447610T1 AT 04734701 T AT04734701 T AT 04734701T AT 04734701 T AT04734701 T AT 04734701T AT E447610 T1 ATE447610 T1 AT E447610T1
Authority
AT
Austria
Prior art keywords
vap
crystalline
usage
present
crystalline vap
Prior art date
Application number
AT04734701T
Other languages
English (en)
Inventor
Tiina Salminen
Tomi Airenne
Mark Johnson
Heidi Kidron
Yvonne Nymalm-Rejstroem
Annu Soederholm
David Smith
Marjo Pihlavisto
Lenita Viitanen
Olli Pentikaeinen
Tommi Nyroenen
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030786A external-priority patent/FI20030786A0/fi
Priority claimed from FI20040271A external-priority patent/FI20040271A0/fi
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ATE447610T1 publication Critical patent/ATE447610T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
AT04734701T 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung ATE447610T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030786A FI20030786A0 (fi) 2003-05-26 2003-05-26 VAP-1:n uusi käyttö
FI20040271A FI20040271A0 (fi) 2004-02-20 2004-02-20 Kiteinen VAP-1 ja sen käyttö
PCT/FI2004/000318 WO2004104191A1 (en) 2003-05-26 2004-05-25 Crystalline vap-1 and uses thereof

Publications (1)

Publication Number Publication Date
ATE447610T1 true ATE447610T1 (de) 2009-11-15

Family

ID=33477699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04734701T ATE447610T1 (de) 2003-05-26 2004-05-25 Kristalliner vap-1 und verwendung

Country Status (11)

Country Link
US (2) US7499847B2 (de)
EP (1) EP1633861B1 (de)
JP (1) JP2007509605A (de)
AT (1) ATE447610T1 (de)
AU (1) AU2004241060B2 (de)
CA (1) CA2526675A1 (de)
DE (1) DE602004023939D1 (de)
DK (1) DK1633861T3 (de)
ES (1) ES2335769T3 (de)
NZ (1) NZ543430A (de)
WO (1) WO2004104191A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040270A0 (fi) * 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset
CN101680850A (zh) * 2007-01-12 2010-03-24 维罗妮卡·詹姆士 计量生物学诊断方法
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
CA2915163A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
US20180360808A1 (en) 2015-12-07 2018-12-20 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580780A (en) 1992-06-09 1996-12-03 Jalkanen; Sirpa Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
RU2204838C2 (ru) * 1997-05-23 2003-05-20 Байотай Терапис Лтд. Сосудистый белок - 1 адгезии, обладающий аминооксидазной активностью
PL342297A1 (en) * 1998-02-06 2001-06-04 Ilexus Pty Ltd Three-dimensional structures and models of fc receptors and their application
CN1450997A (zh) * 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
US7167801B2 (en) * 2001-07-12 2007-01-23 Boehringer Ingelheim (Canada) Ltd. Method of identifying potential inhibitors of human papillomavirus protein E2 using x-ray atomic coordinates
FI20040270A0 (fi) 2004-02-20 2004-02-20 Biotie Therapies Oyj Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset

Also Published As

Publication number Publication date
US7499847B2 (en) 2009-03-03
WO2004104191A1 (en) 2004-12-02
AU2004241060B2 (en) 2009-07-23
ES2335769T3 (es) 2010-04-05
CA2526675A1 (en) 2004-12-02
EP1633861A1 (de) 2006-03-15
WO2004104191A8 (en) 2006-08-17
DK1633861T3 (da) 2010-03-22
AU2004241060A1 (en) 2004-12-02
JP2007509605A (ja) 2007-04-19
EP1633861B1 (de) 2009-11-04
US20070093646A1 (en) 2007-04-26
US20110021760A1 (en) 2011-01-27
DE602004023939D1 (de) 2009-12-17
HK1086591A1 (en) 2006-09-22
NZ543430A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
DE602004027600D1 (de) Genexpressionsmarker für die prognose von brustkrebs
NO20071127L (no) Triazoloftalaziner
BRPI0606379A2 (pt) triazolftalazinas
TW200519089A (en) Biaryl sulfonamides and methods for using same
TW200519100A (en) Biaryl sulfonamides and methods for using same
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
UA93531C2 (en) Novel hydrogen sulfate salt
NO20055741D0 (no) Nye kjemiske forbindelser
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE602004031458D1 (de) Verfahren zur erhöhung der refinerproduktionsrate und/oder verringerung der spezifischen energie des aufschliessens von holz
DE60329326D1 (de) Tace inhibitoren
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
DE602004023939D1 (de) Kristalliner vap-1 und verwendung
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE10342670A1 (de) Isoliertes Photoprotein mtClytin, sowie dessen Verwendung
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
DE602004027086D1 (de) Klassifizierung von kolonkrebs
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
DE60328621D1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633861

Country of ref document: EP

REN Ceased due to non-payment of the annual fee